Literature DB >> 19434831

De novo drug design using multiobjective evolutionary graphs.

Christos A Nicolaou1, Joannis Apostolakis, Costas S Pattichis.   

Abstract

Drug discovery and development is a complex, lengthy process, and failure of a candidate molecule can occur as a result of a combination of reasons, such as poor pharmacokinetics, lack of efficacy, or toxicity. Successful drug candidates necessarily represent a compromise between the numerous, sometimes competing objectives so that the benefits to patients outweigh potential drawbacks and risks. De novo drug design involves searching an immense space of feasible, druglike molecules to select those with the highest chances of becoming drugs using computational technology. Traditionally, de novo design has focused on designing molecules satisfying a single objective, such as similarity to a known ligand or an interaction score, and ignored the presence of the multiple objectives required for druglike behavior. Recently, methods have appeared in the literature that attempt to design molecules satisfying multiple predefined objectives and thereby produce candidate solutions with a higher chance of serving as viable drug leads. This paper describes the Multiobjective Evolutionary Graph Algorithm (MEGA), a new multiobjective optimization de novo design algorithmic framework that can be used to design structurally diverse molecules satisfying one or more objectives. The algorithm combines evolutionary techniques with graph-theory to directly manipulate graphs and perform an efficient global search for promising solutions. In the Experimental Section we present results from the application of MEGA for designing molecules that selectively bind to a known pharmaceutical target using the ChillScore interaction score family. The primary constraints applied to the design are based on the identified structure of the protein target and a known ligand currently marketed as a drug. A detailed explanation of the key elements of the specific implementation of the algorithm is given, including the methods for obtaining molecular building blocks, evolving the chemical graphs, and scoring the designed molecules. Our findings demonstrate that MEGA can produce structurally diverse candidate molecules representing a wide range of compromises of the supplied constraints and thus can be used as an "idea generator" to support expert chemists assigned with the task of molecular design.

Entities:  

Mesh:

Year:  2009        PMID: 19434831     DOI: 10.1021/ci800308h

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  11 in total

Review 1.  Designing antimicrobial peptides: form follows function.

Authors:  Christopher D Fjell; Jan A Hiss; Robert E W Hancock; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

2.  Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets.

Authors:  William J Allen; Brian C Fochtman; Trent E Balius; Robert C Rizzo
Journal:  J Comput Chem       Date:  2017-09-22       Impact factor: 3.376

3.  Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning.

Authors:  Muhetaer Mukaidaisi; Andrew Vu; Karl Grantham; Alain Tchagang; Yifeng Li
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

4.  Automated design of ligands to polypharmacological profiles.

Authors:  Jérémy Besnard; Gian Filippo Ruda; Vincent Setola; Keren Abecassis; Ramona M Rodriguiz; Xi-Ping Huang; Suzanne Norval; Maria F Sassano; Antony I Shin; Lauren A Webster; Frederick R C Simeons; Laste Stojanovski; Annik Prat; Nabil G Seidah; Daniel B Constam; G Richard Bickerton; Kevin D Read; William C Wetsel; Ian H Gilbert; Bryan L Roth; Andrew L Hopkins
Journal:  Nature       Date:  2012-12-13       Impact factor: 49.962

5.  Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib.

Authors:  Martin Klammer; J Nikolaj Dybowski; Daniel Hoffmann; Christoph Schaab
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Bayesian molecular design with a chemical language model.

Authors:  Hisaki Ikebata; Kenta Hongo; Tetsu Isomura; Ryo Maezono; Ryo Yoshida
Journal:  J Comput Aided Mol Des       Date:  2017-03-09       Impact factor: 3.686

7.  Multiobjective de novo drug design with recurrent neural networks and nondominated sorting.

Authors:  Jacob Yasonik
Journal:  J Cheminform       Date:  2020-02-18       Impact factor: 5.514

Review 8.  Advances in de Novo Drug Design: From Conventional to Machine Learning Methods.

Authors:  Varnavas D Mouchlis; Antreas Afantitis; Angela Serra; Michele Fratello; Anastasios G Papadiamantis; Vassilis Aidinis; Iseult Lynch; Dario Greco; Georgia Melagraki
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

9.  LEADD: Lamarckian evolutionary algorithm for de novo drug design.

Authors:  Alan Kerstjens; Hans De Winter
Journal:  J Cheminform       Date:  2022-01-15       Impact factor: 5.514

10.  Network-based piecewise linear regression for QSAR modelling.

Authors:  Jonathan Cardoso-Silva; Lazaros G Papageorgiou; Sophia Tsoka
Journal:  J Comput Aided Mol Des       Date:  2019-10-18       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.